Joseph Maugeri, MD
Gynecology · Landing, NJNPI 1174578017
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $842 of the $1,081 with a category attached, or 77.9%. 24 manufacturers reported payments, led by Astellas Pharma US Inc at 27.1% of the total. Reporting peaked in 2023 at $346 and has fallen 78.4% since, to $75 in 2025.
Across 61 payments — averaging $17.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$293
- AbbVie$162
- Pfizer$128
- Exact Sciences$77
- Therapeuticsmd, Inc.$56
- Biohaven Pharmaceutical Holding Company Ltd.$55
- plus $310 from 18 others
What the payments were for
- Food & beverage$84278%
- Education$23922%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 7 | $293 |
| AbbVie(2 entities) | 10 | $162 |
| Pfizer | 9 | $128 |
| Exact Sciences | 4 | $77 |
| Therapeuticsmd, Inc. | 4 | $56 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $55 |
| Esperion Therapeutics, Inc. | 2 | $29 |
| Novo Nordisk | 2 | $28 |
| Exeltis, USA Inc. | 2 | $27 |
| Hologic Sales And Service, LLC | 2 | $23 |
| Mayne Pharma Commercial LLC | 2 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Davol Inc. | 1 | $17 |
| Bausch Health US, LLC | 1 | $15 |
| Merck | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Aytu Biopharma, Inc. | 1 | $14 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Millicent US Inc | 1 | $13 |
| Organon | 1 | $13 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
| Myovant Sciences Inc. | 1 | $12 |
| Collegium Pharmaceutical, Inc. | 1 | $11 |
How this compares
$1,081 in reported general payments places this provider in the 70th percentile of 97 gynecology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 45 | $2,069 |
| Estradiol (Once Weekly)Estradiol | 13 | $1,821 |
| Ibandronate Sodium | 12 | $532 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 22 | $385 |
| Triamcinolone Acetonide | 25 | $65 |
| Misoprostol | 14 | $41 |
Paid to pharmacies, not to this prescriber.
Other gynecology in Landing
- James TursiLumberton$217K
- Marco PelosiBayonne$164K
- Heather van RaaltePrinceton$140K
- Scott EderPrinceton$124K
- Michael VardyEnglewood$114K
- Daryl BoffardUnion$55K
- Shyama MathewsPlainsboro$54K
- Lora LiuJersey City$36K
- Mark EinsteinNewark$27K
- Jessica Opoku-AnaneNew Brunswick$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.